Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/05/2790924/36989/en/Checkpoint-Therapeutics-Strengthens-Intellectual-Property-Protection-for-Cosibelimab-with-New-U-S-Patent-Issuance.html

Upcoming PDUFA goal date of January 3, 2024

U.S. patent protection for cosibelimab through at least May 2038

WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No. 11,834,505) covering a method of treating various cancers, including cutaneous squamous cell carcinoma (“cSCC”), through the administration of cosibelimab.

Read more at globenewswire.com

Related news for (CKPT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.